Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126074571 | 12607457 | 1 | I | 20160719 | 20160729 | 20160729 | EXP | US-CELGENEUS-USA-2016074912 | CELGENE | MAJD N. CHARACTERIZATION OF CENTRAL NERVOUS SYSTEM MULTIPLE MYELOMA IN THE ERA OF NOVEL THERAPIES. LEUKEMIA + LYMPHOMA. 2016;7:1709-1713. | 59.00 | YR | M | Y | 0.00000 | 20160729 | OT | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126074571 | 12607457 | 1 | PS | THALOMID | THALIDOMIDE | 1 | Oral | U | 20785 | CAPSULES |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126074571 | 12607457 | 1 | Plasma cell myeloma |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126074571 | 12607457 | DE |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126074571 | 12607457 | Plasma cell myeloma |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |